Sasanlimab
Sasanlimab is a pharmaceutical drug with 20 clinical trials. Currently 5 active trials ongoing.
Success Metrics
Phase Distribution
Phase Distribution
16
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
0.0%
0 of 14 finished
100.0%
14 ended early
5
trials recruiting
20
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Clinical Trials (20)
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
All 20 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 20